Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05712889 |
Recruitment Status :
Recruiting
First Posted : February 6, 2023
Last Update Posted : January 12, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Neoplasms | Drug: VIP236 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 24 participants |
Allocation: | N/A |
Intervention Model: | Sequential Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open-label, Multicenter Phase 1 Study to Characterize Safety, Tolerability, Preliminary Antitumor Activity and Pharmacokinetics of VIP236 Monotherapy in Subjects With Advanced Cancer |
Actual Study Start Date : | January 24, 2023 |
Estimated Primary Completion Date : | March 2024 |
Estimated Study Completion Date : | December 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: Dose Escalation of VIP236
Investigating VIP236 in a dose escalation cohort in subjects with advanced solid tumor cancer
|
Drug: VIP236
VIP236 will be administered by IV infusion once every 3 weeks. |
- Incidence of DLT (Dose limit toxicity) of VIP236 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 21 days ]
- Number of participants with adverse events as a measure safety and tolerability [ Time Frame: Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 21 days (up to approximately 10 months) ]
- Disease control rate (DCR) per RECIST v1.1, defined as best overall response of complete response (CR), partial response (PR), or stable disease (SD) as determined by Investigator review. [ Time Frame: Cycle 1 Day 1 up to 30 days after the last dose, where each cycle is up to 21 days (up to approximately 10 months) ]
- Progression-free survival per RECIST v1.1, defined as the time from enrollment to documented disease progression or death from any cause, whichever occurs earlier as determined by Investigator review [ Time Frame: Up to 24 months ]
- Maximum observed drug concentration in measured matrix after single dose administration (Cmax) of VIP236 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 21 days ]
- Area under the concentration versus time curve from zero to infinity after single (first) dose (AUC) of VIP236 [ Time Frame: Cycle 1 Day 1 through Cycle 2 Day 1, where each cycle is up to 21 days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Adult patients aged >/=18 years, able to provide informed consent and willing to comply with all study procedures.
- Histologically confirmed advanced or metastatic solid tumors that are relapsed or refractory to standard of care. Subjects must have exhausted all available standard therapies or be deemed ineligible for potential available therapies.
- Adequate bone marrow, liver, and renal functions.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
Exclusion Criteria:
- Subjects who have new or progressive brain or meningeal or spinal metastases.
- Clinically significant cardiac disease including congestive heart failure > New York Heart Association (NYHA) Class II), evidence for coronary artery disease (eg, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months or myocardial infarction within the past 6 months before first dose.
- Major surgery or significant trauma within 4 weeks before the first dose of study drug.
- Medical history of chronic obstructive pulmonary disease (COPD) and other respiratory disorders.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05712889
Contact: Vincerx Clinical Trials Contact | 1-650-800-6676 | clinicaltrials@vincerx.com |
United States, Arizona | |
Honor Health | Recruiting |
Scottsdale, Arizona, United States, 85258 | |
Contact: Research Site | |
United States, Texas | |
NEXT Austin | Recruiting |
Austin, Texas, United States, 78758 | |
Contact: Research Site | |
NEXT Oncology San Antonio | Recruiting |
San Antonio, Texas, United States, 78229 | |
Contact: Research Site | |
Australia, New South Wales | |
Macquarie University | Recruiting |
Macquarie Park, New South Wales, Australia, 2109 | |
Contact: Research Site | |
Australia, Queensland | |
ICON Brisbane | Recruiting |
Brisbane, Queensland, Australia, 4101 | |
Contact: Research Site | |
Australia, Southern Australia | |
ICON Adelaide | Recruiting |
Adelaide, Southern Australia, Australia, 5037 | |
Contact: Research Site |
Study Director: | Vincerx Study Director | Vincerx Pharma, Inc. |
Responsible Party: | Vincerx Pharma, Inc. |
ClinicalTrials.gov Identifier: | NCT05712889 |
Other Study ID Numbers: |
VNC-236-101 |
First Posted: | February 6, 2023 Key Record Dates |
Last Update Posted: | January 12, 2024 |
Last Verified: | January 2024 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
VIP236 Solid tumors All comers Breast cancer Small cell lung cancer Triple negative breast cancer Colorectal cancer Gastric cancer Lung cancer |
Non-small cell lung cancer Renal cancer Colon cancer Advanced solid tumors Metastatic cancer Bladder cancer Head and neck cancer Esophageal cancer |